INVIVYD INC (IVVD)

US00534A1025 - Common Stock

0.4711  +0.03 (+6.13%)

After market: 0.5053 +0.03 (+7.26%)

INVIVYD INC

NASDAQ:IVVD (12/23/2024, 8:13:26 PM)

After market: 0.5053 +0.03 (+7.26%)

0.4711

+0.03 (+6.13%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-41.67%
Sales Q2Q%N/A
CRS1.31
6 Month-57.17%
Overview
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Ins Owners0.01%
Inst Owners78.39%
Market Cap56.35M
Shares119.62M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts81.82
Short Float %5.04%
Short Ratio7.73
IPO08-06 2021-08-06
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IVVD Daily chart

Company Profile

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Company Info

INVIVYD INC

1601 Trapelo Road, Suite 178

Waltham MASSACHUSETTS

P: 17818190080

Employees: 94

Website: https://invivyd.com/

IVVD Twits

Here you can normally see the latest stock twits on IVVD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example